Nociception

Orion enters into exclusive agreement with Jemincare for novel non-opioid drug candidate for the treatment of pain

Retrieved on: 
Friday, May 6, 2022
Molecule, Greater, Research and development, Brain, Pain, Senior, Orion Corporation, NAV, Corporation, Patient, Pediatrics, Neuron, Cerebro, Nephrology, Therapy, Patent, Neurology, R, Achievement, Chronic pain, Nav1.8, Nociception, Ownership, Central nervous system, Pharmaceutical industry, IND, Research

Orion will also receive ownership to certain key patent applications relating to the compound within its own territory.

Key Points: 
  • Orion will also receive ownership to certain key patent applications relating to the compound within its own territory.
  • According to the agreement, Orion has the right to develop and commercialise the asset in its territory.
  • In addition, Jemincare is eligible to receive tiered royalty of 8% to 15% on future sales in Orion territory.
  • We are excited about this agreement and are looking forward to taking this compound to clinical studies later this year.

OKYO Pharma ("OKYO" or the "Company") - Announces Two Presentations at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Retrieved on: 
Wednesday, April 27, 2022
BAM, Official List, UK, Financial Conduct Authority, Poster, Cornea, Biotechnology, Pain, Perception, LSE, NCP, ARVO, MAP, Annual general meeting, Association, Tufts Medical Center, Eye, Regulation of tobacco by the U.S. Food and Drug Administration, Duane syndrome, Association for Research in Vision and Ophthalmology, Nociception, MD, Food, Model, Molecule, GLOBE, Ocular neuropathic pain, Steroid, Infection, London Stock Exchange Group, Technology, CO, Company, MA, Industry, Quality of life, Risk, Peripheral neuropathy, Interim, London Stock Exchange, Research, Pharmaceutical industry, Vaccine, Ophthalmology

LONDON, April 27, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, today announced that two presentations will be given on OKYO drug candidates OK-101 and OK-201 at the Association for Research and Vision in Ophthalmology (ARVO) Annual Meeting, to be held on May 1-4, 2022 in Denver, CO and virtually on May 11-12, 2022.

Key Points: 
  • OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain.
  • Millions of people suffer from ocular pain every year with no treatment approved by the U.S. Food and Drug Administration for this condition.
  • Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements.
  • The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made.

WIMI Hologram Academy: Progress of virtual reality technology in hospice care

Retrieved on: 
Tuesday, April 12, 2022
Cloud, HMD, Hospice, Purging disorder, Awareness, Pain, Pain management, COPD, Hygiene, Meditation, Culture, Palliative care, COVID-19, Advance care planning, Adult, Virtual reality, Software, NASDAQ, Research, Nociception, Anxiety, Life, Caregiver, Immersion, Empathy, Science, GLOBE, Education, Patient, Neoplasm, VR, WIMI, ACP, Technology, Student, Psychological pain, Environment, Imagination, Depression, Dizziness, Maintenance, AI, Randomized controlled trial, Emotion, HIV disease progression rates, Nursing, Partnership, Face, Risk, Nausea, Time, Fatigue, Video game console, Residential care, Medicine

Scientists who are from WIMI Hologram Academy of WIMI Hologram Cloud Inc.(NASDAQ: WIMI), discussed Virtual Reality technology has important applications in hospice care to reduce pain, anxiety, and depression at the end of life; develop hospice care teams, and improve the effectiveness of advance care plans and family counseling.

Key Points: 
  • Scientists who are from WIMI Hologram Academy of WIMI Hologram Cloud Inc.(NASDAQ: WIMI), discussed Virtual Reality technology has important applications in hospice care to reduce pain, anxiety, and depression at the end of life; develop hospice care teams, and improve the effectiveness of advance care plans and family counseling.
  • With the maturity of virtual reality technology, virtual reality technology should be applied and studied in hospice care.
  • Based on it, the application progress of virtual reality technology in the field of hospice care is summarized to promote the application of virtual reality technology.
  • There are four main types of virtual reality technologies used in the medical care field: desktop virtual reality system, immersive virtual reality system, enhanced virtual reality system and distributed virtual reality system.

Emergex Signs Agreement with ATCC to Advance Studies of its Yellow Fever Booster Vaccine Candidate

Retrieved on: 
Thursday, April 7, 2022
Central, T cell, LinkedIn, WHO, Fever, Dengue fever, Public health, Coronavirus, Research, Egg, Prevalence, ATCC, Mosquito-borne disease, MHC, Safety, Infection, Twitter, Climate, Science, Drug discovery, Flaviviridae, CD8, Nociception, History, Collection, Vaccine, Yellow fever, Chikungunya

Emergex has a growing pipeline of innovative CD8+ T-Cell Adaptive Vaccine and booster vaccine candidates that have the potential to deliver rapid, broad (mutation-agnostic) and long-lasting immunity to reduce serious illness associated with infectious disease.

Key Points: 
  • Emergex has a growing pipeline of innovative CD8+ T-Cell Adaptive Vaccine and booster vaccine candidates that have the potential to deliver rapid, broad (mutation-agnostic) and long-lasting immunity to reduce serious illness associated with infectious disease.
  • Other programmes in development include vaccine candidates for universal (pandemic) Influenza, Chikungunya, and a booster vaccine for Yellow Fever.
  • With potential stability at ambient temperatures, the vaccine candidates as intended reduce the burden and logistics of vaccine administration.
  • Yellow Fever is a severe, potentially fatal, mosquito-borne disease endemic to tropical and subtropical regions of Africa, Central and South America.

DGAP-News: Evotec receives € 3 m milestone payment for Bayer starting Phase II clinical development of DNP programme

Retrieved on: 
Monday, March 21, 2022
Nociception, Company, LinkedIn, Therapy, NASDAQ, Neurology, MDAX, Diabetes, News, DGAP, Frankfurt Stock Exchange, Research, Biotechnology, ESG, BAY, ISIN, Phase II, Quality of life, Safety, Twitter, Mark (given name), Brain, BDKRB1, Science, DNP, Bayer, EVO, Nerve Damage, Patient, Phase, Security (finance), Pharmaceutical industry, Fine chemical, Evotec

DNP is a common chronic condition associated with nerve damage caused by high blood sugar levels in diabetic patients.

Key Points: 
  • DNP is a common chronic condition associated with nerve damage caused by high blood sugar levels in diabetic patients.
  • DNP may be triggered through the slightest touch upon which the body sends unprompted pain signals to the brain.
  • Bayer has initiated a Phase II clinical trial to evaluate the safety and efficacy of BAY 2395840 in patients with DNP compared to placebo.
  • Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We are excited that Bayer is moving ahead with the Phase II clinical development of an asset from our multi-target research alliance.

MDoloris Medical Systems & Mindray Announce the CE Mark and Launch of Their Analgesia Nociception Index MR Module in Europe

Retrieved on: 
Wednesday, December 15, 2021
Technology, Surgery, Medical Devices, Hospitals, Venture Capital, Other Technology, Professional Services, Cardiology, Health, Hospital, Technology, Solution, Anesthesia, Varian Medical Systems, Neuroscience, BMBS, Medical device regulation, Monitoring, Nociception, Doctor of Philosophy, Heart rate, Autonomic nervous system, BSCI, Asensio, Observational study, Health, Pain, CEO, General manager, Patient, PONV, CE marking, Ageing, ANI, Post, MBBS, Neurocognition, Volume, Partnership, FANZCA, Paola Lattus, Medical device, Dentistry, Mindray, Honours degree, Analgesic, MD, Laminectomy, Orthopedic surgery, the Analgesia Nociception Index, MDoloris Medical Systems, Mindray, THE ANALGESIA NOCICEPTION INDEX, MDOLORIS MEDICAL SYSTEMS, MINDRAY

MDoloris Medical Systems, leader in the field of objective analgesia/nociception monitoring during anesthesia and in intensive care, and Mindray, a global leader in developing and providing advanced medical devices and solutions, announce today the CE Mark and upcoming launch of the Mdoloris ANI-MR module.

Key Points: 
  • MDoloris Medical Systems, leader in the field of objective analgesia/nociception monitoring during anesthesia and in intensive care, and Mindray, a global leader in developing and providing advanced medical devices and solutions, announce today the CE Mark and upcoming launch of the Mdoloris ANI-MR module.
  • Were very excited to announce that we will launch the ANI-MR module on January 1st, 2022.
  • Obtaining the CE Mark under the new Medical Device Regulation for our ANI MR module is a critical milestone for Mdoloris.
  • The upcoming launch of the module by our partner Mindray will be a major step forward, considerably strengthening MDoloris reach into thousands of Operating Rooms in Europe.

DRUG DISCOVERY PARTNERSHIP ANNOUNCED IN UAE

Retrieved on: 
Wednesday, December 15, 2021
Method, Tarnow, Failure, S4, Bedford Stem Cell Research Foundation, Hospital, COVID, AIDS, Solution, CRISPR, FDA, United States Air Force Scientific Advisory Board, Springer Nature, White House, Sickle cell disease, The Coca-Cola Company, Biology, Physician, Cell, Doctor of Philosophy, Learning, Global health, Intelligence, Technology, CNS, Industry, Rockefeller University, Lists of diseases, Nobel Prize, Genetics, HIV, Degenerative disease, AI, The, Drug discovery, Diet, Genetic engineering, Research, Biotechnology, Disease, Goal, Patient, Nociception, Public health surveillance, Kraft Foods, International, Flow cytometry, Efficiency, Data collection, DRS, Partnership, Epithelial sodium channel, ACTI, Pharmaceutical industry, Fine chemical, Tutoring, Medical device, Thalassemia, Nestlé, MD

In the pharmaceutical drug discovery and development process, Chromovert is a cutting-edge technology that goes beyond CRISPR by enabling the creation of previously out-of-reach designer cells for improved drug discovery.

Key Points: 
  • In the pharmaceutical drug discovery and development process, Chromovert is a cutting-edge technology that goes beyond CRISPR by enabling the creation of previously out-of-reach designer cells for improved drug discovery.
  • According to Dr. Shekdar, "Our technology can have a global impact on genetics and cell research, particularly in the area of rare genetic diseases drug discovery.
  • By strategically locating in the UAE, we enhance data collection in that region and can prioritize drug discovery against new and relevant targets."
  • Currently, the industry average failure rate for drug discovery programs in pharmaceutical companies is reported to be approximately 98%.

Biofrontera Inc. Announces Notice of Allowance for U.S. Patent on Innovative Illumination Protocol

Retrieved on: 
Thursday, December 2, 2021
Patent, Photodynamic therapy, BFRI, Private Securities Litigation Reform Act, Face, Company, United States Patent and Trademark Office, LSA, SEC, DUSA Pharmaceuticals, Scalp, COVID-19, Nociception, Dermatology, BF, Nasdaq, GLOBE, Health, Impetigo, Marketing, PDT, FDA, XL, USPTO, Pharmaceutical industry, Medical imaging

This patented illumination protocol demonstrates Biofronteras commitment to the patients need for innovative treatments.

Key Points: 
  • This patented illumination protocol demonstrates Biofronteras commitment to the patients need for innovative treatments.
  • The patent application claims a method for photodynamic therapy in which a dynamic and innovative illumination protocol is implemented.
  • This protocol consists of changing illumination intensities combined in a predefined order with interruptions of the illumination to specifically modulate and reduce pain perception to the patient.
  • Implementation of the protocol to Biofronteras medical devices requires a software installation and can be rolled-out to both the BF-RhodoLED and BF-RhodoLED XL lamps.

International Technology Company Eybna Empowers the Next Generation of Wellness Products with Receptor-Specific™ Formulations

Retrieved on: 
Wednesday, October 20, 2021
Psilocybin, CB1, Doctor of Philosophy, Pain, Terpene, Technology, Memory, Cannabinoid, Cannabis, Life, Research, CBD, Anxiety, North Hall, CB2, Quality of life, Health, TRPV1, Learning, Inflammation, GABAergic, Sleep, Science, Nociception, US, CPG, Research and development, Medicinal plants, Pharmaceutical industry

The core technology behind these formulations is the culmination of nearly a decade of scientific research and biological data analysis.

Key Points: 
  • The core technology behind these formulations is the culmination of nearly a decade of scientific research and biological data analysis.
  • Eybna will showcase their full line of products including the new Functional Line Receptor-Specific formulations at MJBizCon in Las Vegas from October 20-22.
  • For additional information on Eybna, its products, technology, science and white papers, please visit www.eybna.com or contact Avichai Elbaz at [email protected] .
  • Eybna is a pioneering technology company and terpene manufacturer with US HQ offices in California and R&D centers in Israel and Colorado.

uniQure Announces Presentations at the Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)

Retrieved on: 
Tuesday, October 19, 2021
ALS, AAV, Nociception, IND, Annual general meeting, GLA, Liver, European Society of Gene and Cell Therapy, NASDAQ, CNS, Neuron, GB3, Technology, Gene, COVID-19, Kidney, Cell, Fabry disease, Haemophilia, Spinal cord, Time, TLE, Type III, CEST, Disease, Epilepsy, Central nervous system, IPSC, Program, Research, C9orf72, Spinocerebellar ataxia, Risk, GLOBE, Brain, Patient, Huntington's disease, Temporal lobe epilepsy, ESGCT, Forward-looking statement, Efficiency, Heart, Phenotype, Locomotion, GRIK2, Pharmaceutical industry, Vaccine

and AMSTERDAM, The Netherlands, Oct. 19, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that four data presentations, including one oral presentation, will be delivered at the European Society of Gene and Cell Therapy (ESGCT) 28th Annual Meeting taking place virtually today through October 22, 2021.

Key Points: 
  • and AMSTERDAM, The Netherlands, Oct. 19, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that four data presentations, including one oral presentation, will be delivered at the European Society of Gene and Cell Therapy (ESGCT) 28th Annual Meeting taking place virtually today through October 22, 2021.
  • AMT-191 is a one-time administered AAV5 gene therapy incorporating an -galactosidase A (GLA) transgene.
  • Moreover, pre-clinical studies in non-human primates with AMT-191 demonstrated robust and sustained increases in GLA activity in multiple organs.
  • uniQure is delivering on the promise of gene therapy single treatments with potentially curative results.